user
menu
letter
Sign InRegister
langEnglisharrow

Monoclonal Anti-SN38 Antibody, Mouse IgG1

Antibody Internalization Detection Reagent (IGG-PZF2001) monitors endocytosis in live cells
製品番号/仕様
価格
Availability
数量
SN8-M685-100ug
$800.00
In Stock - Delivery in 2-3 business days
SN8-M685-1mg
$5,330.00
In Stock - Delivery in 2-3 business days
SN8-M685
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
Request Quote
製品詳細
データ表示
Reviews & Citations
Resources
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-SN38 Antibody, Mouse IgG1 is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to mouse IgG1 constant domains.

Antibody Type

Recombinant Monoclonal

Clone

AM685

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Immunogen

SN38-OVA

Specificity

Specifically recognizes the target-SN38.

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

バックグランド

SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.